

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: ALB1/22 - Albumin in Urine

Deadline: 08.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>									
<b>(369) Albumin</b>											249	232	93%		
Samples and groups	[mg/L]														
<b>Sample A</b>		33,0	2,4	7,4	249	CVP	33	0,38	21%	26	40	249	238	96%	
(1) Abbott		34,6	1,6	4,6	63	0						63			
(12) Beckman Coulter		33,4	2,5	7,4	6	0						6			
(58) Beckman Coulter (AU)		33,4	1,2	3,5	38	0						38			
(60) Roche		32,3	1,9	5,8	88	0						88			
(162) Siemens (Atellica)		28,7	1,2	4,3	15	0						15			
(179) Siemens		31,2	2,1	6,8	15	0						15			
Other					24	0						24			
							1x 0, 1x 5, 1x 36, 2x 46, 4x 49, 3x 75, 1x 91, 1x 116, 3x 149, 3x 152, 3x 177, 1x 999						249	239	96%
<b>Sample B</b>		182	14	7,8	249	CVP	182	2,2	21%	143	221	249	239	96%	
(1) Abbott		194	11	5,7	63	0						63			
(12) Beckman Coulter		175	4,4	2,5	6	0						6			
(58) Beckman Coulter (AU)		182	7,3	4,0	38	0						38			
(60) Roche		181	8,1	4,5	88	0						88			
(162) Siemens (Atellica)		155	3,2	2,1	15	0						15			
(179) Siemens		161	12	7,4	15	0						15			
Other					24	0						24			
							1x 0, 1x 5, 1x 36, 2x 46, 4x 49, 3x 75, 1x 91, 1x 116, 3x 149, 3x 152, 3x 177, 1x 999								
<b>(408) Creatinine</b>												237	234	99%	
Samples and groups	[mmol/L]														
<b>Sample A</b>		5,41	0,29	5,3	237	CVP	5,41	0,045	16%	4,54	6,28	237	234	99%	
(0) not specified		5,40	0,44	8,2	8	0						8			
(1) Abbott		5,25	0,20	3,9	54	0						54			
(46) Erba Lachema		5,36	0,30	5,6	10	0						10			
(58) Beckman Coulter (AU)		5,48	0,34	6,2	38	0						38			
(60) Roche		5,51	0,24	4,3	84	0						84			
(162) Siemens (Atellica)		5,25	0,19	3,7	15	0						15			
(179) Siemens		5,48	0,26	4,8	14	0						14			
Other					14	0						14			
							2x 5, 2x 12, 2x 49, 2x 116, 1x 158, 1x 166, 2x 177, 2x 196								
<b>Sample B</b>		5,99	0,30	5,0	237	CVP	5,99	0,048	16%	5,03	6,95	237	234	99%	
(0) not specified		6,01	0,58	9,6	8	0						8			
(1) Abbott		5,80	0,27	4,7	54	0						54			
(46) Erba Lachema		5,95	0,38	6,5	10	0						10			
(58) Beckman Coulter (AU)		6,14	0,23	3,8	38	0						38			
(60) Roche		6,07	0,27	4,4	84	0						84			
(162) Siemens (Atellica)		5,85	0,20	3,5	15	0						15			
(179) Siemens		6,08	0,26	4,3	14	0						14			
Other					14	1						14			
							2x 5, 2x 12, 2x 49, 2x 116, 1x 158, 1x 166, 2x 177, 2x 196								
<b>(470) ACR</b>												232	220	95%	
Samples and groups	[g/mol]														
<b>Sample A</b>		6,09	0,62	10	232	CVP	6,09	0,10	24%	4,62	7,56	232	224	97%	
(0) not specified		6,09	0,62	10	232	0						232			
<b>Sample B</b>		30,4	3,2	11	232	CVP	30,4	0,52	24%	23,1	37,7	232	226	97%	
(0) not specified		30,4	3,2	11	232	1						232			

st\_kn\_p

End of report

Printed: 11.04.2022